Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

NCT04676529 is registered in ClinicalTrials.gov with Syntara as lead sponsor.

NCT NCT04676529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Lead sponsor
Syntara
Phase
Phase 1/2
Overall status
Completed
Start date
February 18, 2021
Completion date
July 9, 2025
Enrollment
43 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post polycythemia vera myelofibrosis, post- essential thrombocythemia myelofibrosis, primary myelofibrosis (pmf)